US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Inspire Corporate Bond ETF

23.70

+0.04830.20%

Volume:82.02K

Turnover:1.94M

Market Cap:381.57M

PE:- -

High:23.78

Open:23.68

Low:23.61

Close:23.65

Loading ...

Overview Company News Filings

Palatin Announces Positive Topline Results from Phase 2 Ulcerative Colitis (UC) Study of Oral Melanocortin-1 Receptor Agonist PL8177

Spyre Therapeutics Announces First Participant Dosed in Phase 1 Trial of SPY003, its Novel Half-life Extended IL-23 Antibody

Organovo Provides Business Update

Shattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights

Press Release: Organovo Announces Close of the Sale of FXR Program to Eli Lilly and Company

Tharimmune Announces Positive Results for Novel Oral Monoclonal Antibody TH023 Targeting Tumor Necrosis Factor-alpha

ACCESS Newswire

Press Release: Organovo Announces Reverse Stock Split

Kaspa’s Crescendo Hardfork Approaching Fast: Update

Spyre Therapeutics Announces Grants of Inducement Awards

BIMZELX® (bimekizumab-bkzx) Two-Year Data at AAD Showed Potential to Eliminate Draining Tunnels in Hidradenitis Suppurativa, and Reduction in Disease Burden

BIMZELX® (bimekizumab-bkzx) Five-Year Data at AAD 2025 Showed Sustained Skin Clearance and Long-Term Efficacy in Moderate-to-Severe Plaque Psoriasis

Organovo Announces the Issuance of Additional Shares in Conjunction with Warrant Exercises

Here's How to Play AbbVie Stock as it Enters the Obesity Space

SKYRIZI® (risankizumab) Now Available for Moderately to Severely Active Ulcerative Colitis, Expanding AbbVie's Portfolio Across Inflammatory Bowel Disease

Press Release: Ventyx Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Corporate Progress

Kymera Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/IBD/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"IBD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBD\",,,,,undefined,":{"symbol":"IBD","market":"US","secType":"STK","nameCN":"Inspire Corporate Bond ETF","latestPrice":23.7,"timestamp":1743192000000,"preClose":23.6517,"halted":0,"volume":82018,"delay":0,"floatShares":16100000,"shares":16100000,"eps":0,"marketStatus":"Pre-Market Trading","change":0.0483,"latestTime":"03-31 05:26:55 EDT","open":23.68,"high":23.78,"low":23.6101,"amount":1942983.290924,"amplitude":0.007183,"askPrice":29.06,"askSize":100,"bidPrice":19.06,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1743427800000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":23.7,"sharesOutstanding":16100000,"nav":23.7,"aum":381617015.71,"bidAskSpread":0.006226,"postHourTrading":{"tag":"盘后","latestPrice":23.7,"preClose":23.7,"latestTime":"18:35 EDT","volume":3,"amount":71.1,"timestamp":1743201311282},"volumeRatio":2.2354441894898427},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBD\",,,,,undefined,":{"symbol":"IBD","floatShares":16100000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":2.2354441894898427,"shares":16100000,"dividePrice":0.9757,"high":23.78,"amplitude":0.007183,"preClose":23.6517,"low":23.6101,"week52Low":22.84,"pbRate":"--","week52High":25.49,"institutionHeld":0,"latestPrice":23.7,"eps":0,"divideRate":0.041169,"volume":82018,"delay":0,"ttmEps":0,"open":23.68,"prevYearClose":23.44,"prevWeekClose":23.7,"prevMonthClose":23.81,"prevQuarterClose":23.44,"fiveDayClose":23.77,"twentyDayClose":23.81,"sixtyDayClose":23.56},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IBD\",pageSize:16,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2522573773","title":"Palatin Announces Positive Topline Results from Phase 2 Ulcerative Colitis (UC) Study of Oral Melanocortin-1 Receptor Agonist PL8177","url":"https://stock-news.laohu8.com/highlight/detail?id=2522573773","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522573773?lang=en_us&edition=fundamental","pubTime":"2025-03-28 19:30","pubTimestamp":1743161400,"startTime":"0","endTime":"0","summary":"Clinical Remission: Achieved in 33% of PL8177-treated patients versus 0% on placebo after eight weeks of treatment.Clinical Response : Demonstrated in 78% of PL8177-treated patients versus 33% on placebo after eight weeks of treatment .Symptomatic Remission: Achieved in 56% of PL8177-treated patients versus 33% on placebo after eight weeks of treatment.Clinical remission was achieved in 33%  of PL8177-treated patients versus 0%  on placebo.Clinical response is defined per FDA Guidance  as a decrease from baseline in themMS of greater than or equal to 2 points and at least a 30% from baseline, and a decrease in rectal bleeding subscore of greater than or equal to 1","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/palatin-announces-positive-topline-results-113000236.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/palatin-announces-positive-topline-results-113000236.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","IBD","PTN","SFS"],"gpt_icon":0},{"id":"2522595385","title":"Spyre Therapeutics Announces First Participant Dosed in Phase 1 Trial of SPY003, its Novel Half-life Extended IL-23 Antibody","url":"https://stock-news.laohu8.com/highlight/detail?id=2522595385","media":"PR Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522595385?lang=en_us&edition=fundamental","pubTime":"2025-03-28 04:05","pubTimestamp":1743105900,"startTime":"0","endTime":"0","summary":"Preclinical data demonstrates that SPY003 is highly potent and has potential forquarterly or biannual dosing, suggesting opportunity for improved efficacy andconvenience over first-generation anti-IL-23 monoclonal antibodies. Interim pharmacokinetic and safety data from healthy volunteers for SPY003 anticipatedin the second half of 2025. SPY003 is an investigational, novel, extended half-life monoclonal antibody targeting IL-23, being developed for the potential treatment of IBD. IBD is a chronic condition characterized by inflammation in the gastrointestinal tract and encompasses two main disorders: ulcerative colitis and Crohn's disease. In the United States, it is estimated that approximately 2.4 million individuals currently have IBD. In head-to-head preclinical studies, SPY003 demonstrated equivalent potency to risankizumab in inhibiting pSTAT signaling and IL-17 production and exhibited significantly longer half-life in non-human primates with the potential to deliver dosing in h","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/spyre-therapeutics-announces-first-participant-200500981.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/spyre-therapeutics-announces-first-participant-200500981.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4218","BK4139","BK4181","SYRE","IBD","LENZ","PK"],"gpt_icon":0},{"id":"2522824370","title":"Organovo Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2522824370","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522824370?lang=en_us&edition=fundamental","pubTime":"2025-03-27 20:05","pubTimestamp":1743077100,"startTime":"0","endTime":"0","summary":"SAN DIEGO, March 27, 2025  -- Organovo Holdings, Inc.  , a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease  today provided a business update.Organovo’s 3D human cellular models of both Crohn’s disease and ulcerative colitis are used by the company to evaluate therapeutic opportunities. Organovo believes that targets and therapies that it finds attractive based on predictive date from these models, made with primary cells from IBD patients, have a greater chance of success in clinical trials. Stated Organovo Executive Chairman Keith Murphy, “As we demonstrated in 2024 with FXR, we can position an asset for a significant return to investors using our 3D human cellular models of IBD. We expect to tailor our going forward business plan to leverage our newly replenished capital levels to pursue such opportunities.”","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/organovo-provides-business-120500269.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1093756325.SGD","LU0122379950.USD","LU2237443622.USD","LU2237443895.HKD","LU2237443978.SGD","LU2491050154.USD","IE0002141913.USD","LU1868836914.USD","LU2468319806.SGD","BK4533","SGXZ51526630.SGD","IE0009355771.USD","LU1974910355.USD","SGXZ31699556.SGD","LU2491049909.HKD","LU0689472784.USD","IBD","LU2237443382.USD","LU2089984988.USD","SG9999014898.SGD","LU1868837136.USD","LU0094547139.USD","LU0471298694.HKD","LU1291159041.SGD","LU0238689110.USD","LU2211815571.USD","IE00B4R5TH58.HKD","LU1868837300.USD","LU0203201768.USD","LU2106854487.HKD","LU0079474960.USD","IE00B2B36J28.USD","IE00BK4W5M84.HKD","LU0882574055.USD","LU2237443549.SGD","LU1917777945.USD","LU1069344957.HKD","LU0466842654.USD","LU1061106388.HKD","LU1093756168.USD","LU2264538146.SGD","LLY","BK4007","LU2602419157.SGD","ONVO","LU2237438978.USD","LU1064131342.USD","LU2265009873.SGD","LU0203202063.USD","LU0354030438.USD"],"gpt_icon":0},{"id":"2522375405","title":"Shattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2522375405","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522375405?lang=en_us&edition=fundamental","pubTime":"2025-03-27 19:00","pubTimestamp":1743073200,"startTime":"0","endTime":"0","summary":"– Presented preclinical non-human primate  data at the 20th Congress of European Crohn’s and Colitis Organization in Inflammatory Bowel Diseases 2025  for SL-325, a potentially first-in-class blocking antibody to DR3, the receptor for TL1A; data demonstrated favorable safety profile, full receptor occupancy, lack of DR3 agonism –。– SL-325 advances toward Phase 1; on track for IND filing in the third quarter of 2025 –。– Cash balance of approximately $73.0 million as of December 31, 2024, expected to fund operations into 2027 –。AUSTIN, TX and DURHAM, NC, March 27, 2025  -- Shattuck Labs, Inc.  , a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor  superfamily receptors for the treatment of patients with inflammatory and immune-mediated diseases, today reported financial results for the fourth quarter and full year ended December 31, 2024 and provided recent business highlights.Shattuck’s lead product candidate, SL-325, is a potentially","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/shattuck-labs-reports-fourth-quarter-110000089.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","STTK","IBD"],"gpt_icon":0},{"id":"2522800949","title":"Press Release: Organovo Announces Close of the Sale of FXR Program to Eli Lilly and Company","url":"https://stock-news.laohu8.com/highlight/detail?id=2522800949","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522800949?lang=en_us&edition=fundamental","pubTime":"2025-03-25 23:25","pubTimestamp":1742916300,"startTime":"0","endTime":"0","summary":"SAN DIEGO, March 25, 2025  -- Organovo Holdings, Inc.  , a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease , today announced the successful close of the sale of its FXR program, including lead asset FXR314, to Eli Lilly and Company  .   The transaction was completed on March 25, 2025.With the closing, Organovo receives an upfront payment, with future milestones to be paid as FXR314 hits key regulatory and commercial milestones. Lilly is acquiring all commercial and intellectual property rights to Organovo's FXR program for worldwide development and will be responsible for all future clinical development.Organovo is a clinical stage biotechnology company that is developing drugs that are demonstrated to be effective in three-dimensional  human tissues as candidates for drug development. The company has proprietary technology used to build 3D human tissues that mimic key aspects of native human tissue composition, archit","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0114720955.EUR","LU2360106947.USD","LU0385154629.USD","SGXZ51526630.SGD","LU2237443465.HKD","LU1064131342.USD","LU0106261372.USD","LU2063271972.USD","LU1720051108.HKD","SG9999014906.USD","SG9999014898.SGD","LU0256863902.USD","LU1983299246.USD","SG9999017495.SGD","LU0289739699.SGD","IE0009355771.USD","LU0109391861.USD","LU2237443622.USD","FXR","ONVO","SG9999014880.SGD","LU2461242641.AUD","LU1548497426.USD","LU1035775433.USD","LU1988902786.USD","LU0456855351.SGD","LU1057294990.SGD","LU0708995401.HKD","SG9999015986.USD","LU1868836757.USD","IE00BJJMRZ35.SGD","BK4139","LU0471298777.SGD","LU2602419157.SGD","IBD","LU1917777945.USD","LU0203201768.USD","LU0417517546.SGD","LU1868837300.USD","LU1291159041.SGD","LU0466842654.USD","LLY","LU0096364046.USD","LU0354030511.USD","LU1623119135.USD","LU0471298694.HKD","IE0004445239.USD","IE00BK4W5M84.HKD","LU2106854487.HKD","BK4534"],"gpt_icon":0},{"id":"2521725882","title":"Tharimmune Announces Positive Results for Novel Oral Monoclonal Antibody TH023 Targeting Tumor Necrosis Factor-alpha","url":"https://stock-news.laohu8.com/highlight/detail?id=2521725882","media":"ACCESS Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521725882?lang=en_us&edition=fundamental","pubTime":"2025-03-24 20:00","pubTimestamp":1742817600,"startTime":"0","endTime":"0","summary":"BRIDGEWATER, NJ / ACCESS Newswire / March 24, 2025 / Tharimmune, Inc.  , a clinical-stage biotechnology company focused on immunology and inflammation, today announced positive preclinical results for its novel oral antibody, TH023. In a murine model, a proprietary protease enzyme stabilized platform demonstrated successful delivery of infliximab, a tumor necrosis factor-alpha  inhibitor, in serum with concentrations detected being significantly higher than the standard serum trough concentration needed for antibody efficacy in immunology indications via injection . These findings represent a significant step towards developing a more convenient and potentially patient-preferred alternative to currently available infliximab treatments, which are administered via intravenous infusion or subcutaneous injection.The Company announced last year through a partnership with Intract Pharma, an exclusive license to INT-023 (now","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tharimmune-announces-positive-results-novel-120000890.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PBC","THAR","IBD","BK4218","PK","BK4181","BK4139"],"gpt_icon":0},{"id":"2520183653","title":"Press Release: Organovo Announces Reverse Stock Split","url":"https://stock-news.laohu8.com/highlight/detail?id=2520183653","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520183653?lang=en_us&edition=fundamental","pubTime":"2025-03-19 20:05","pubTimestamp":1742385900,"startTime":"0","endTime":"0","summary":"SAN DIEGO, March 19, 2025  -- Organovo Holdings, Inc. , a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease , today announced that it will effect a 1-for-12 reverse stock split of its issued and outstanding common stock that will become effective at 5:00 p.m. Eastern Time on Thursday, March 20, 2025. Organovo's common stock will commence trading on a reverse stock split-adjusted basis at the opening of the market on Friday, March 21, 2025.Following the reverse stock split, Organovo's common stock will continue to trade on the Nasdaq Capital Market under the symbol \"ONVO\" with a new CUSIP number of 68620A302.Organovo's transfer agent, Continental Stock Transfer & Trust Company, will provide information to stockholders regarding their stock ownership following the reverse split and cash in lieu of fractional share payments, if applicable. Stockholders holding their shares in book-entry form or through a bank, broker or oth","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBD","ONVO","NQmain","BK4139"],"gpt_icon":0},{"id":"2518635063","title":"Kaspa’s Crescendo Hardfork Approaching Fast: Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2518635063","media":"CoinMarketCap","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518635063?lang=en_us&edition=fundamental","pubTime":"2025-03-12 16:44","pubTimestamp":1741769082,"startTime":"0","endTime":"0","summary":"Kaspa is making headway with its development inside the blockchain space. The Proof-of-Work L1 protocol has provided additional information concerning its expansive Crescendo Hardfork. This upgrade seeks to increase the network’s block rate from 1 to 10 blocks per second .Recently, the protocoltook to X to announce that Testnet 10  has fully transitioned to 10 BPS. This milestone is critically important for the blockchain following the Hardfork activation on March 7, 2025.TN10 aims to transform Kaspa into one of the swiftest PoW blockchains with the help of its revolutionary GHOSTDAG protocol that permits the parallel creation and confirmation of blocks. This successful shift establishes a clear agenda for the next milestone, which will be monumental for the platform and its global decentralized blockchain infrastructure.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://coinmarketcap.com/community/articles/67d1497bf908dc328c14ed31/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"coinmarketcap_highlight","symbols":["BK4585","IE00BFXG0V08.USD","FAST","BK4588","IE00BYQQ9H92.USD","BK4567","BK4104","IBD","IE00B5TLWC47.USD"],"gpt_icon":0},{"id":"2517466136","title":"Spyre Therapeutics Announces Grants of Inducement Awards","url":"https://stock-news.laohu8.com/highlight/detail?id=2517466136","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517466136?lang=en_us&edition=fundamental","pubTime":"2025-03-08 05:40","pubTimestamp":1741383600,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., March 7, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc.  , a clinical-stage biotechnology company utilizing best-in-class antibody engineering, dose optimization and rational therapeutic combinations to target improved efficacy and convenience in the treatment of IBD and other immune-mediated diseases, today announced that Spyre's independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase 132,200 shares of common stock of Spyre to five non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended . The stock options were approved on March 3, 2025 and were material to each employee's acceptance of employment with Spyre, in accordance with Nasdaq Listing Rule 5635.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/spyre-therapeutics-announces-grants-inducement-214000337.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/spyre-therapeutics-announces-grants-inducement-214000337.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IBD","BK4139","LENZ","SYRE"],"gpt_icon":0},{"id":"2517803824","title":"BIMZELX® (bimekizumab-bkzx) Two-Year Data at AAD Showed Potential to Eliminate Draining Tunnels in Hidradenitis Suppurativa, and Reduction in Disease Burden","url":"https://stock-news.laohu8.com/highlight/detail?id=2517803824","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517803824?lang=en_us&edition=fundamental","pubTime":"2025-03-07 21:00","pubTimestamp":1741352400,"startTime":"0","endTime":"0","summary":"Over half of patients had no draining tunnels  at two years: In 425 hidradenitis suppurativa  patients with ≥1 DTs at baseline, 55.7%  had no DTs at two years of treatment.≠ DTs are painful, pus-discharging tunnels under the skin resulting from long-term inflammation, frequently leading to scarring. Clinically meaningful relief from skin pain: At two years of BIMZELX treatment, 63.6%  of patients reported no or mild skin pain, compared to 10.0%  at baseline≠。Sustained disease control across patient populations: Improvements in HiSCR50* and HiSCR75* sustained up to two years, regardless of age, sex, disease duration or severity, demonstrating efficacy regardless of patient demographics≠。ATLANTA, March 7, 2025 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced two-year data from the BE HEARD^ trials for BIMZELX  in moderate-to-severe hidradenitis suppurativa . BIMZELX, the first and only medicine approved to selectively inhibit both interleukin 17A  and interleukin ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/bimzelx-bimekizumab-bkzx-two-data-130000049.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bimzelx-bimekizumab-bkzx-two-data-130000049.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4111","BK4202","LU2023250504.SGD","PSO","UCBJY","LU2298321311.HKD","LU0868494617.USD","LU2048586759.USD","BK4204","IE00B2PGVK34.USD","BK4086","LU2092937221.SGD","OC","LU1974910355.USD","LU2023250843.SGD","BK4007","AS","IE00B3CCJ633.GBP","IBD","LU1917777945.USD","LU2360108059.USD","IE00BGHQF417.EUR","LU2041044095.USD","UCBJF","LU2106854487.HKD"],"gpt_icon":0},{"id":"2517480804","title":"BIMZELX® (bimekizumab-bkzx) Five-Year Data at AAD 2025 Showed Sustained Skin Clearance and Long-Term Efficacy in Moderate-to-Severe Plaque Psoriasis","url":"https://stock-news.laohu8.com/highlight/detail?id=2517480804","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517480804?lang=en_us&edition=fundamental","pubTime":"2025-03-07 21:00","pubTimestamp":1741352400,"startTime":"0","endTime":"0","summary":"Sustained complete skin clearance over five years: In a subset of 153 patients from the second extension of BE BRIGHT, 67.7% of patients with moderate-to-severe plaque psoriasis  treated with BIMZELX  achieved PASI100+ at five years. Durable and broad efficacy across patient subgroups at four years: Consistently high rates of complete or near-complete skin clearance seen at four years regardless of baseline weight or baseline cardiometabolic comorbidities such as hypertension, hyperglycemia, or elevated BMI. High response rates in patients at risk of psoriatic arthritis at three years: Data showed 68.7–71.6% of PSO patients at risk of developing psoriatic arthritis  achieved complete skin clearance, generally consistent with the overall treated group. Similar results were seen in all patients with PSO, including those with PsA at baseline. \"Psoriasis is a chronic condition that increases the risk of developing other serious health issues,\" said Fiona du Monceau, Executive Vice Presiden","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/bimzelx-bimekizumab-bkzx-five-data-130000473.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bimzelx-bimekizumab-bkzx-five-data-130000473.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AS","UCBJY","BK4202","BK4204","IBD","BK4007","BK4111","UCBJF","PSO"],"gpt_icon":0},{"id":"2517508511","title":"Organovo Announces the Issuance of Additional Shares  in Conjunction with Warrant Exercises","url":"https://stock-news.laohu8.com/highlight/detail?id=2517508511","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517508511?lang=en_us&edition=fundamental","pubTime":"2025-03-06 21:05","pubTimestamp":1741266300,"startTime":"0","endTime":"0","summary":"SAN DIEGO, March 06, 2025  -- Organovo Holdings, Inc.  , a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease  today announced it has issued additional shares in conjunction with warrant exercises by investors and at-the-market stock sales. An additional 2,967,144 shares of common stock of the Company have been issued. The shares of common stock issuable upon exercise of the outstanding warrants were registered pursuant to a registration statements that was declared effective on May 8, 2024. The aggregate gross proceeds from the exercise of the existing warrants and at-the-market stock sales are expected to total approximately $2.3 million, before deducting financial advisory fees and commissions. After giving effect to the issuance of these additional shares, the Company has 20,421,617 shares of outstanding common stock.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/organovo-announces-issuance-additional-shares-130500505.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","ONVO","IBD"],"gpt_icon":1},{"id":"2517878943","title":"Here's How to Play AbbVie Stock as it Enters the Obesity Space","url":"https://stock-news.laohu8.com/highlight/detail?id=2517878943","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517878943?lang=en_us&edition=fundamental","pubTime":"2025-03-05 21:38","pubTimestamp":1741181880,"startTime":"0","endTime":"0","summary":"Earlier this week, AbbVie ABBV announced that it is in-licensing rights to develop phase I candidate, GUB014295, along-acting amylin analog for the treatment of obesity, from Danish research company, Gubra.While the obesity field is greatly dominated by GLP-1 products, the amylin hormone is gaining steam as a potential target for treating obesity. It regulates appetiteby slowing down stomach emptying, which makes a person feel full and helps prevent overeating.AbbVie will lead the development of the candidate. For the deal, AbbVie will pay Gubra an upfront payment of $350 millionand be entitled to make milestone payments of up to $1.875 billion to the latter.The obesity market has gained tremendous popularity and is expected to reach $100 billion by 2030, per a Goldman Sachs report. Eli Lilly LLY and Novo Nordisk NVO currently dominate the space with their respective GLP-1 drugs Zepbound and Wegovy. However, several large drugmakers like Merck MRK, Pfizer, Amgen, and AstraZeneca, among","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/heres-play-abbvie-stock-enters-133800732.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2023250504.SGD","LU0417517546.SGD","IE00BJLML261.HKD","ABBV","LU0006306889.USD","LU1430594728.SGD","LU1699723380.USD","SG9999013999.USD","SG9999001176.SGD","LU0823416689.USD","CD","BK4007","BK4559","IBD","LU1989772840.SGD","LU0882574055.USD","LU0097036916.USD","GB00BDT5M118.USD","IE00B2B36J28.USD","LU1732800096.USD","SG9999002224.SGD","SG9999018865.SGD","LU0109391861.USD","LU0198837287.USD","LU0553294199.USD","LU1548497426.USD","LU1839511570.USD","LU0795875086.SGD","LU2491050154.USD","MRK","SGXZ81514606.USD","LU0795875169.SGD","LU2063271972.USD","LU0965508806.USD","LU1917777945.USD","LU0320765646.SGD","LU1868837136.USD","IE00BVYPNW00.USD","LU0234570918.USD","LU0354030438.USD","IE00BK4W5M84.HKD","LU2106854487.HKD","LU1093756325.SGD","LU2491050071.SGD","LU0689472784.USD","LU1366192091.USD","LU0070302665.USD","LU0266013472.USD"],"gpt_icon":1},{"id":"2516676496","title":"SKYRIZI® (risankizumab) Now Available for Moderately to Severely Active Ulcerative Colitis, Expanding AbbVie's Portfolio Across Inflammatory Bowel Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2516676496","media":"CNW Group","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516676496?lang=en_us&edition=fundamental","pubTime":"2025-03-04 21:00","pubTimestamp":1741093200,"startTime":"0","endTime":"0","summary":"SKYRIZI is the first IL-23 specific inhibitor approved for both moderate to severe ulcerative colitis and moderate to severe Crohn's disease.1. MONTREAL, March 4, 2025 /CNW/ -AbbVie announced today that SKYRIZI  is now available in Canada for the treatment of adults with moderately to severely active ulcerative colitis  who have had an inadequate response, loss of response, or were intolerant to conventional therapy, a biologic treatment, or a Janus kinase  inhibitor1, following Health Canada approval of this indication in October 2024. SKYRIZI is now approved for four indications across immune-mediated inflammatory diseases.\"We are so grateful for the approval of SKYRIZI for ulcerative colitis and hopeful it will have a positive effect on patient healing,\" said Gail Attara, CEO and co-founder of the Gastrointestinal Society. \"Ulcerative colitis is a debilitating inflammatory bowel disease. Given the uniqueness of each individual, it's essential to bring new treatment options for ulcer","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/skyrizi-risankizumab-now-available-moderately-130000496.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4566","BK4550","BK4534","LU1037948897.HKD","IBD","LU1267930490.SGD","LU0211328371.USD","LU1934455277.USD","IE00BJJMRZ35.SGD","LU1551013425.SGD","LU1732799900.SGD","LU2089283258.USD","LU0912757837.SGD","LU1291159041.SGD","LU0310800379.SGD","LU1244550577.SGD","LU1037948541.HKD","LU2237443978.SGD","LU0170899867.USD","LU0949170772.SGD","LU2133065610.SGD","LU0965509101.SGD","SG9999015945.SGD","LU1093756325.SGD","LU0029864427.USD","LU0661504455.SGD","IE0004445239.USD","LU0965509283.SGD","BK4581","LU0128525929.USD","LU1430594728.SGD","LU1496350171.SGD","LU1267930573.SGD","IE00B4R5TH58.HKD","LU1989772923.USD","SG9999003800.SGD","ABBV","LU1732800096.USD","LU0795875169.SGD","IE00BJT1NW94.SGD","LU1496350502.SGD","LU1839511570.USD","LU1244550494.USD","IE0009355771.USD","LU1934455194.USD","LU0861579265.USD","SG9999015986.USD","IE0002141913.USD","IE00B3PB1722.GBP","LU1983299246.USD"],"gpt_icon":0},{"id":"2514433053","title":"Press Release: Ventyx Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Corporate Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2514433053","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514433053?lang=en_us&edition=fundamental","pubTime":"2025-02-28 05:05","pubTimestamp":1740690300,"startTime":"0","endTime":"0","summary":"Ventyx Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Corporate Progress. Topline data readouts from multiple Phase 2 studies expected throughout 2025. -- VTX2735 in patients with recurrent pericarditis in H2. -- VTX3232 in participants with obesity and cardiometabolic risk factors in. -- VTX3232 biomarker study in patients with early Parkinson's disease in Q2. Cash, cash equivalents and marketable securities balance of $252.9M as of. December 31, 2024 expected to fund operations into at least H2 2026. results are expected in the second half of 2025.By treating and preventing disease recurrence, VTX2735 has the potential to offer a safe, effective, and convenient oral therapy for patients suffering from recurrent pericarditis.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBD","PRGS","BK4097","VTYX","LU2065732104.USD"],"gpt_icon":0},{"id":"2514180598","title":"Kymera Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2514180598","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514180598?lang=en_us&edition=fundamental","pubTime":"2025-02-27 20:00","pubTimestamp":1740657600,"startTime":"0","endTime":"0","summary":"KT-621  Phase 1 healthy volunteer trial ongoing, complete SAD/MAD data expected in June 2025. KT-621 Phase 1b trial in atopic dermatitis  patients expected to initiate in 2Q25 with data in 4Q25, followed by two parallel Phase 2b trials in AD and asthma starting in 4Q25 and 1Q26, respectively. KT-295  Phase 1 trial is expected to start in 2Q25, with data expected in 4Q25. KT-474/SAR444656  Phase 2b trials in hidradenitis suppurativa  and AD ongoing, led by partner Sanofi, with primary completion of both trials expected by mid-2026. New oral degrader program against a high-value immunology target to be announcedin early May 2025 in a company webcast. STAT6 Degrader ProgramKT-621 is an investigational, first-in-class, once daily, oral degrader of STAT6, the specific transcription factor responsible for IL-4/IL-13 signaling and the central driver of Th2 inflammation. In preclinical studies, KT-621 demonstrated dupilumab-like activity in several in vitro and in vivo models and was safe and ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/kymera-therapeutics-announces-fourth-quarter-120000004.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","PN","IBD","KYMR","LENZ"],"gpt_icon":0}],"pageSize":16,"totalPage":13,"pageCount":1,"totalSize":200}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IBD\",params:#limit:5,,,undefined,":[{"date":"2025-03-27","symbol":"IBD","amount":0.092,"announcedDate":"2025-03-26","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-27","defaultRemindTime":1743082200000,"name":"Inspire Corporate Bond ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-01","payableDate":"2025-03-27","currency":"USD","dateTimestamp":1743048000000,"payDate":"2025-04-01"},{"date":"2025-02-24","symbol":"IBD","amount":0.0728,"announcedDate":"2025-02-21","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-02-24","defaultRemindTime":1740407400000,"name":"Inspire Corporate Bond ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-03","payableDate":"2025-02-24","currency":"USD","dateTimestamp":1740373200000,"payDate":"2025-03-03"},{"date":"2025-01-27","symbol":"IBD","amount":0.0599,"announcedDate":"2025-01-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-01-27","defaultRemindTime":1737988200000,"name":"Inspire Corporate Bond ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-02-03","payableDate":"2025-01-27","currency":"USD","dateTimestamp":1737954000000,"payDate":"2025-02-03"},{"date":"2024-12-16","symbol":"IBD","amount":0.1181,"announcedDate":"2024-12-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-16","defaultRemindTime":1734359400000,"name":"Inspire Corporate Bond ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-23","payableDate":"2024-12-16","currency":"USD","dateTimestamp":1734325200000,"payDate":"2024-12-23"},{"date":"2024-11-22","symbol":"IBD","amount":0.0748,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-11-22","defaultRemindTime":1732285800000,"name":"Inspire Corporate Bond ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-11-29","payableDate":"2024-11-22","currency":"USD","dateTimestamp":1732251600000,"payDate":"2024-11-29"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IBD\",market:\"US\",,,undefined,":[{"executeDate":"2017-08-16","recordDate":"2017-08-18","paymentDate":"2017-08-23","value":0.0405,"currency":"USD"},{"executeDate":"2017-09-18","recordDate":"2017-09-19","paymentDate":"2017-09-25","value":0.0292,"currency":"USD"},{"executeDate":"2017-10-16","recordDate":"2017-10-17","paymentDate":"2017-10-23","value":0.0347,"currency":"USD"},{"executeDate":"2017-11-16","recordDate":"2017-11-17","paymentDate":"2017-11-28","value":0.0389,"currency":"USD"},{"executeDate":"2018-01-29","recordDate":"2018-01-30","paymentDate":"2018-02-05","value":0.0269,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IBD\",market:\"US\",delay:false,,,undefined,":{}}}